Revenue and earnings declines, combined with rising restructuring costs and shrinking patient/clinic base, signal ongoing operational stress. The accelerated buyback completion reduces share count but does not offset deteriorating fundamentals. Monitor Q2 for TDAPA tailwind fading (expected H2 2026) and further FME25+ cost impacts. The stock's market cap below book value warrants attention for potential impairment risk.
Price Chart
Executive Summary
Fresenius Medical Care reported Q1 2026 results with revenue of €4,612M, down 6% YoY as reported (up 3% constant currency), and operating income of €286M, down 14% YoY (down 9% constant currency). Net income attributable to shareholders fell 22% to €118M, driven by €166M in FME25+ restructuring costs, higher personnel expenses, and inflationary pressures, partially offset by TDAPA reimbursement benefits and business growth in Care Delivery.
Key Facts
- Revenue decreased 6% YoY to €4,612M (up 3% constant currency); operating income fell 14% to €286M (down 9% constant currency)
- Net income attributable to shareholders down 22% to €118M; basic EPS fell 17% to €0.43 from €0.52
- FME25+ Program costs of €166M in Q1 2026 (vs €28M in Q1 2025), including €105M in impairment losses from clinic closures
- Care Delivery operating income fell 15% to €271M; Value-Based Care swung to an operating loss of €11M from income of €3M
- Patient count declined 3% to 289,923; dialysis treatments down 3% to 10.67M; clinics reduced by 4% to 3,539
- Share buyback accelerated: 23.3M shares repurchased for €940.6M through March 31, 2026; program completed early at 24.8M shares (8.5% of capital)
- Net leverage ratio increased to 2.6x from 2.5x at year-end 2025; ROIC slipped to 4.9% from 5.0%
- Market cap of €10.4B below shareholders' equity of €13.2B, though no impairment indicated
Financial Impact
Revenue declined €269M YoY; operating income fell €45M; net income attributable to shareholders dropped €34M
Risk Factors
- FME25+ restructuring costs expected to remain elevated through 2027, with €1.2B cumulative savings target
- TDAPA reimbursement benefits expected to decline starting H2 2026, pressuring Care Delivery margins
- U.S. regulatory headwinds: OBBBA Medicaid cuts, Marietta ruling impact on commercial insurance mix, potential ACA premium tax credit expiration effects
- China volume-based procurement and tariff uncertainty creating cost and revenue pressure
- Goodwill of €13.8B (44% of total assets) at risk if market cap remains below equity
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-055376 |
| Document: fms-20260331xex31d2.htm | 0001104659-26-055376 |
| Document: fms-20260331xex31d1.htm | 0001104659-26-055376 |
| Document: fms-20260331xex32d1.htm | 0001104659-26-055376 |
| Document: fms-20260331xex32d2.htm | 0001104659-26-055376 |
| Document: 0001104659-26-055376-index-headers.html | 0001104659-26-055376 |
| Document: 0001104659-26-055376-index.html | 0001104659-26-055376 |
| Document: 0001104659-26-055376.txt | 0001104659-26-055376 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 28, 2026 21w ago | 6-K | $42.00 $51.44 | ▲ +22.48% | ▲ +20.74% | $43.82 (+4.33%) |
May 26, 2026 22w ago | 6-K | $42.00 $51.44 | ▲ +22.48% | ▲ +19.75% | $43.82 (+4.33%) |
May 5, 2026 25w ago | 6-K | $43.08 $49.82 | ▼ −15.65% | ▼ −12.91% | $43.82 (−1.72%) |
Apr 14, 2026 28w ago | 6-K | $44.25 $44.59 | ▲ +0.77% | ▼ −7.75% | $43.82 (−0.97%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers